spreading agent

spreading agent

a substance that modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid.
Mentioned in ?
References in periodicals archive ?
Communication and spreading agent for the services of the Federal Employment Agency.
As a spreading agent, hyaluronidase has traditionally been used to accelerate the delivery of drugs and fluids, including local anesthetics, other co-injected drugs, and contrast agents, and for subcutaneous fluid replacement.
Food and Drug Administration for use as a spreading agent to increase the absorption and dispersion of other injected drugs and for subcutaneous hydration.
On June 7th, ISTA announced FDA approval of Istalol for glaucoma, which is the company's second FDA approval; the company announced FDA approval for Vitrase as a spreading agent in May.
2, 2005, for use as a spreading agent to increase the absorption and dispersion of other injected drugs and for subcutaneous hydration.
ISTA's Vitrase(R) (Ovine Hyaluronidase) is FDA-approved for use as a spreading agent, for hypodermoclysis, and as an adjunct in subcutaneous urography.
Hylenex is a recombinant human hyaluronidase approved for use as a spreading agent to accelerate the delivery of fluids and drugs, such as local anesthesics and other co-injected drugs, contrast agents, and for subcutaneous fluid replacement.
FDA's approval of Vitrase for use as a spreading agent in May 2004 removed hyaluronidase from the FDA's drug shortage list where it had been listed since 2001.
In May 2004, the FDA approved Vitrase(R) in a lyophilized 6200 USP Units multi-purpose vial for use as a spreading agent; a 200 USP Units/mL vial in sterile solution for use as a spreading agent was approved in December 2004.
today announced its Fall 2005 schedule for presenting clinical data on its product, Vitrase(R) (Ovine Hyaluronidase), which is currently FDA approved for use as a spreading agent for hypodermoclysis and as an adjunct in subcuteanous urography.
Halozyme submitted the Hylenex NDA on March 23, 2005, seeking approval for use as a spreading agent to facilitate the dispersion and absorption of other drugs.
Enhanze SC(TM), the first product in Halozyme's Enhanze(TM) Technology portfolio, is a formulation of recombinant human hyaluronidase under development for use as a spreading agent to enhance the delivery of local anesthesia, contrast agents, and for subcutaneous fluid replacement (also called hypodermoclysis).